Detalles de la búsqueda
1.
Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients?
BMC Cancer
; 22(1): 323, 2022 Mar 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35337281
2.
Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study.
BMC Cancer
; 22(1): 1047, 2022 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36203123
3.
High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study.
J Transl Med
; 19(1): 92, 2021 02 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-33639962
4.
Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.
BMC Cancer
; 17(1): 302, 2017 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28464801
5.
Cerebral infarction in advanced non-small cell lung cancer: a case control study.
BMC Cancer
; 16: 203, 2016 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26964872
6.
Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease.
BMC Cancer
; 14: 508, 2014 Jul 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-25012241
7.
Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small-cell lung cancer.
Thorac Cancer
; 14(5): 442-449, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36523162
8.
Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Thorac Cancer
; 12(3): 329-338, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33219754
9.
Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Cancer Chemother Pharmacol
; 76(4): 771-6, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26259641
Resultados
1 -
9
de 9
1
Próxima >
>>